Whitehawk Therapeutics (WHWK) Stock Statistics & Valuation Metrics

Whitehawk Therapeutics has a market cap or net worth of $184.54M. The enterprise value is $146.23M.

Whitehawk Therapeutics has 47,196,564 shares outstanding. The number of shares has decreased by -2.65% in one year.

Whitehawk Therapeutics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -83.93%.

The current PE Ratio of Whitehawk Therapeutics is ―. Whitehawk Therapeutics’s PEG ratio is 0.08.

In the last 12 months, Whitehawk Therapeutics had revenue of 7.14M and earned -20.60M in profits. Earnings per share was -0.33.

In the last 12 months, operating cash flow was -97.43M and capital expenditures -552.00K, giving a free cash flow of -97.98M billion.

Whitehawk Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Whitehawk Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Whitehawk Therapeutics as a current ratio of 10.26, with Debt / Equity ratio of 0.00%

In the past 12 months, Whitehawk Therapeutics has paid 0.00 in taxes.

Whitehawk Therapeutics EV to EBITDA ratio is -0.98, with an EV/FCF ratio of -1.15.

Whitehawk Therapeutics has $145.70M in cash and marketable securities with $0.00 in debt, giving a net cash position of $145.70M billion.

Gross margin is 89.28%, with operating margin of -1601.12%, and net profit margin of -288.26%.

The average price target for Whitehawk Therapeutics is $6.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy